Floatz logo

Thioguanine Anhydrous

Lymphoblastic Lymphoma

St. Jude Children's Research HospitalSmall moleculePhase 4 / ApprovedActive
BB
71/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
70/ 100
Competitive Position
73/ 100

Competitive context

73 Active assets in the Lymphoblastic Lymphoma cohort.

Asset / SponsorPhaseRating
Cladribine
Fifth Affiliated Hospital, Sun Yat-Sen University
Phase 4BBB
Rituximab
University of Washington
Phase 4BBB
Vindesine
University Hospital Muenster
Phase 4BBB
Mercaptopurine Anhydrous
City of Hope Medical Center
Phase 4BBB
Etoposide
University of Washington
Phase 4BBB

View all 50 →

Same molecule, other indications

Thioguanine Anhydrous is also rated in:

B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative · Phase 3
73 / 100
View asset →
acute lymphoblastic leukemiaActive
BBB
Indicative · Phase 4
72 / 100
View asset →
B-cell adult acute lymphocytic leukemiaDormant
BB
Indicative · Phase 3
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →